| |
Join industry leaders at HLTH 2023 on October 8-11 in Las Vegas - featuring the NEW Pharma & Life Sciences Insights Program – for a deep dive into the world of digital technologies. Register here!
|
|
Today’s Big NewsAug 15, 2023 |
| By Kevin Dunleavy Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far. Meanwhile, only six of the industry’s top 20 firms experienced revenue decreases, with Pfizer's sales dropping a whopping 54%. |
|
|
|
By James Waldron Gilead Sciences' $225 million bet on Arcellx’s CAR-T cell therapy is back in play after the FDA lifted a clinical hold instigated in the wake of a patient death. |
By Andrea Park Just as remediation efforts in Philips' massive 2021 respiratory device recall wind down, the company is now facing yet another Class I recall of some of its ventilators. |
By Fraiser Kansteiner Biogen’s $7.3 billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month. But it turns out Biogen wasn’t the only drugmaker jockeying for the Texas-based rare disease outfit, a new securities filing shows. |
By Annalee Armstrong Tentarix Biotherapeutics is emerging from its den to ink a multi-pronged deal with Gilead Sciences to work on therapies for oncology and inflammatory diseases worth $66 million upfront, including an equity payment. |
By Zoey Becker The omicron variant EG.5, or "Eris," has taken hold as the new dominant variant in the U.S., leaving vaccine makers rushing to make sure their new shots can hold up. |
By Andrea Park More than a year after unveiling its wearable, wireless patient monitoring system—with CE mark already in hand, allowing it to be used across Europe—GE HealthCare is bringing the Portrait Mobile technology across the pond. |
By Max Bayer Alaunos Therapeutics is cutting loose its sole clinical-stage asset and letting 60% of staff go less than two years after rebranding and refocusing on TCR-T cell therapies. |
By Fraiser Kansteiner Responding to recent acquisition rumors, Stada Arzneimittel's CEO Peter Goldschmidt told the German Press Agency, “Whether and when STADA might be sold is solely the decision of our owners; Bain Capital and Cinven.” |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we take a closer look at intersectionality and a group that has been ignored: intersex individuals. |
|
|---|
|
|
|
From the team behind Fierce Pharma, Fierce Biotech, and Fierce Healthcare, Fierce Life Sciences Events. Explore our up-coming events this Fall, there's something for everyone! Secure your spot and save today!
|
|
| Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
